Author:
Conley John M.,Mitchell Robert,Cadigan R. Jean,Davis Arlene M.,Dobson Allison W.,Gladden Ryan Q.
Abstract
The current ethical norms of genomic biobanking creating and maintaining large repositories of human DNA and/or associated data for biomedical research have generated criticism from every angle, at both the practical and theoretical levels. The traditional research model has involved investigators seeking biospecimens for specific purposes that they can describe and disclose to prospective subjects, from whom they can then seek informed consent. In the case of many biobanks, however, the institution that collects and maintains the biospecimens may not itself be directly involved in research, instead banking the biospecimens and associated data for other researchers. Moreover, the future uses of biospecimens may be unknown, if not unknowable, at the time of collection. Biobanking may thus stretch the meanings of inform and consent to their breaking point: if you cannot inform subjects about what their biospecimens will be used for (because you do not know), what can they consent to? Given that informed consent by individual subjects is the ethical gold standard, the seeming dilution of the concept in the context of biobanking is a profound problem.
Publisher
Cambridge University Press (CUP)
Subject
Health Policy,General Medicine,Issues, ethics and legal aspects
Reference71 articles.
1. 15. Mitchell, R. Conley, J. Davis, A. Cadigan, J. Dobson, A. Gladden, R. , "Genomics, Biobanks, and the Trade-Secret Model,"Science 332, no. 6027 (April 15, 2011): 309-310
2. see also, "Letters and Response," Science 333, no. 6051 (September 16, 2011): 1574-1576.
3. 48. Id., at 573.
4. 27. See Tutton, supra note 21, at 538; Waldby, Mitchell, supra note 23, at 19.
5. The consent problem within DNA biobanks
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献